A London-based medtech start-up has raised US$7m (£5.9m) to advance personalised stroke rehabilitation.
Neurofenix combines a telemedicine platform with the sensor-based Neuroball device to offer personalised rehab to people with stroke, brain injury and spinal cord injury.
Patients use the Neuroball for the rehabilitation of arm and hand functions through games and tracking features performed through an app.
The device includes a motion and orientation sensor for wrist, elbow and shoulder movements, and individual sensors for each finger. The ball rests in a cradle but can be picked up and moved freely.
It tracks every movement of the upper limbs from shoulder down to fingertips, allowing patients to perform rehab exercises and movements more frequently with supervision and on their own, in a way that reflects their particular needs and capabilities.
The US$7m Series A funding was led by AlbionVC and will be used for US expansion, recruitment and clinical trials.
Every year over 100,000 people in the UK have a stroke at an estimated £3bn cost to the NHS, plus an extra £4bn in productivity, disability and informal care.
“Neurofenix is poised to revolutionise physical recovery after neurological injuries such as stroke, traumatic brain injury or spinal cord injury,” said Andrew Elder, deputy managing partner at AlbionVC.
“With my experience as a neurosurgeon, I see that Neurofenix can fill a big gap in the neurorehabilitation industry.”
Neurofenix, a digital therapeutics company, was founded in 2016 by CEO Guillem Singla Buxarais and CTO Dimitrios Athanassiou to empower patients and their families to get their life back after suffering a stroke, traumatic brain injury or spinal cord injury.
The start-up is actively selling the NeuroBall platform to survivors, rehabilitation clinics and institutions for upper extremity recovery.
The digital therapy device can be used in the clinic and at home.
